R&D Day

24 Jul 2007 07:30

Summit Corporation PLC24 July 2007 SUMMIT plc (formerly VASTox plc) TO HOLD R&D DAY IN LONDON On 24 July 2007, Summit plc, a leading UK biotechnology company formerly knownas VASTox plc, is today holding an R&D day in London for investors, analysts andmembers of the press. The programme of presentations will cover various aspectsof Summit plc's enhanced drug pipeline, its clinical programmes and thepotential of its zebrafish screening and carbohydrate chemistry platforms,following its recent acquisitions of MNL Pharma, Daniolabs and DextraLaboratories. In addition, Professor Francesco Muntoni, Professor of Paediatric Neurology atthe Hammersmith Hospital, and Dr Paul Goldsmith, a consultant neurologist atAddenbrookes Hospital, will provide clinical perspectives on the areas ofneuromuscular diseases and Parkinson's disease, respectively. The event, which is being held at the offices of Huntsworth Health plc, 8thFloor, 26 Finsbury Square, London EC2A 1SF, begins at 10.00am and is followed bya buffet lunch. For further information and to register interest in attending, please contactValerie Auffray or Janine Hagan at Citigate Dewe Rogerson on +44 (0)207 282 1068or email janine.hagan@citigatedr.co.uk The agenda is outlined below: 10:00 Welcome, Tea & Coffee 10:10 Dr Barry Price Welcome and introduction Chairman, Summit plc 10:15 Dr Richard Storer Overview of drug portfolio & twin technology Chief Scientific Officer, Summit plc platforms 10:35 Dr Paul Goldsmith Parkinson's disease: sialorrhoea and Consultant Neurologist, Addenbrookes Hospital seborrhoea - a clinician's perspective 10:55 Dr Nigel Blackburn The clinical development plan for the Director of Clinical Development, Summit plc Parkinson's disease programmes 11:10 Break 11:15 Professor Francesco Muntoni Neuromuscular diseases: a clinical focus Paediatric Neurologist, Hammersmith Hospital and Imperial College 11:35 Dr Jon Tinsley Summit plc's neuromuscular disease programmes: Director of Therapeutic Programmes, Summit a focus on Duchenne muscular dustrophy plc 11:55 Dr Alan Roach Zebrafish: the in vivo advantage Director of Biology, Summit plc 12:10 Professor Robert Nash Carbohydrates: an emerging technology for the Director of Research, Summit plc development of new drugs (Aberystwyth) 12:30 Buffet Lunch - ends - For more information please contact: Summit plcSteven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951Darren Millington, ACMA, Chief Financial Officer Citigate Dewe RogersonMark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571 Evolution SecuritiesTim Worlledge / Bobbie Hilliam / Neil Elliot Tel: +44 (0)207 071 4300 About Summit plc Summit plc is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced carbohydrate chemistry and drug screening (chemicalgenomics) technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. Summit plc has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. Summit plc's in-house drug development capabilities combine world-classexpertise in both carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering datathat are highly predictive of the efficacy and toxicity of potential drugcompounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: SUMM Further information about the company is available at www.summitplc.com This document contains "forward-looking statements" within the meaning of theU.S. Private Securities Litigation Reform Act of 1995. Forward-lookingstatements can be identified by words such as "anticipates", "intends", "plans","seeks", "believes", "estimates", "expects" and similar references to futureperiods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations andassumptions regarding our business, the economy and other future conditions.Because forward-looking statements relate to the future, by their nature, theyare subject to inherent uncertainties, risks and changes in circumstances thatare difficult to predict. The Company's actual results may differ materiallyfrom those contemplated by the forward-looking statements. The Company cautionsyou therefore that you should not rely on any of these forward-lookingstatements as statements of historical fact or as guarantees or assurances offuture performance. Important factors that could cause actual results to differmaterially from those in the forward-looking statements and regional, national,global political, economic, business, competitive, market and regulatoryconditions. This information is provided by RNS The company news service from the London Stock Exchange